Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens

Ann Hematol. 2022 Feb;101(2):465-467. doi: 10.1007/s00277-021-04525-9. Epub 2021 Apr 16.

Authors

Rikako Tabata¹, Nobue Sato², Nobuhiko Yamauchi¹, Yong-Mei Guo¹, Hirotaka Nakamura¹, Akihito Nagata¹, Chi Song-Gi¹, Yosuke Minami¹, Junichiro Yuda³

Affiliations

¹ Department of Hematology, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa, Chiba, 277-8577, Japan.
² Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan.
³ Department of Hematology, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa, Chiba, 277-8577, Japan. jyuda@east.ncc.go.jp.

PMID: 33864134
DOI: 10.1007/s00277-021-04525-9

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytomegalovirus Infections / virology
Cytomegalovirus* / drug effects
Cytomegalovirus* / physiology
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / virology
Virus Activation* / drug effects

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
daratumumab